Idioma:

miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin

Zhu, X ; Shen, H ; Yin, X ; Long, L ; Xie, C ; Liu, Y ; Hui, L ; Lin, X ; Fang, Y ; Cao, Y ; Xu, Y ; Li, M ; Xu, W ; Li, Y

Oncogene, 2016-01, Vol.35 (3), p.323-332 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin
Autor: Zhu, X ; Shen, H ; Yin, X ; Long, L ; Xie, C ; Liu, Y ; Hui, L ; Lin, X ; Fang, Y ; Cao, Y ; Xu, Y ; Li, M ; Xu, W ; Li, Y
Assuntos: Adult ; Aged ; Analysis ; Animals ; Apoptosis ; Apoptosis - drug effects ; Care and treatment ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Chemotherapy ; Cisplatin ; Cisplatin - administration & dosage ; Development and progression ; Drug resistance ; Drug Resistance, Neoplasm - genetics ; Epithelial-Mesenchymal Transition - genetics ; Female ; Gene Expression Regulation, Neoplastic - drug effects ; Genotype & phenotype ; Health aspects ; Humans ; Mice ; MicroRNAs ; MicroRNAs - biosynthesis ; MicroRNAs - genetics ; Middle Aged ; Neoplasm Staging ; Nuclear Proteins - biosynthesis ; Nuclear Proteins - genetics ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - pathology ; Prognosis ; Protein expression ; Stem cell research ; Twist-Related Protein 1 - biosynthesis ; Twist-Related Protein 1 - genetics ; Xenograft Model Antitumor Assays
É parte de: Oncogene, 2016-01, Vol.35 (3), p.323-332
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Epithelial-mesenchymal transition (EMT) has an established role in promoting tumor progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. Furthermore, luciferase reporter and rescue assay results showed that the EMT and drug resistance reversal in response to miR-186 was mediated by Twist1. Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin

Zhu, X ; Shen, H ; Yin, X ; Long, L ; Xie, C ; Liu, Y ; Hui, L ; Lin, X ; Fang, Y ; Cao, Y ; Xu, Y ; Li, M ; Xu, W ; Li, Y

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.